These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 25817520)

  • 21. Substantia nigra hyperechogenicity as a marker for Parkinson's disease: a population-based study.
    Mahlknecht P; Seppi K; Stockner H; Nocker M; Scherfler C; Kiechl S; Willeit J; Schmidauer C; Gasperi A; Rungger G; Poewe W
    Neurodegener Dis; 2013; 12(4):212-8. PubMed ID: 23689066
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A population-based study on combined markers for early Parkinson's disease.
    Tunc S; Graf J; Tadic V; Brüggemann N; Schmidt A; Al-Khaled M; Wolff S; Vollstedt EJ; Lorwin A; Hampf J; Piskol L; Klein C; Hagenah J; Kasten M
    Mov Disord; 2015 Apr; 30(4):531-7. PubMed ID: 25546094
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Does normal substantia nigra echogenicity make a difference in Parkinson's disease diagnosis? A real clinical practice follow-up study.
    Alonso-Canovas A; Lopez-Sendon Moreno JL; Buisan J; Sainz de la Maza S; Costa-Frossard L; Garcia-Ribas G; de Felipe-Mimbrera A; Matute-Lozano MC; Zarza Sanz B; Toledano Delgado R; Corral I; Masjuan J; Martinez-Castrillo JC
    J Neurol; 2018 Oct; 265(10):2363-2369. PubMed ID: 30116942
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relationship of substantia nigra echogenicity and motor function in elderly subjects.
    Berg D; Siefker C; Ruprecht-Dörfler P; Becker G
    Neurology; 2001 Jan; 56(1):13-7. PubMed ID: 11148229
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transcranial sonography in the premotor diagnosis of Parkinson's disease.
    Behnke S; Schröder U; Berg D
    Int Rev Neurobiol; 2010; 90():93-106. PubMed ID: 20692496
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prodromal Parkinson's disease as defined per MDS research criteria in the general elderly community.
    Mahlknecht P; Gasperi A; Willeit P; Kiechl S; Stockner H; Willeit J; Rungger G; Sawires M; Nocker M; Rastner V; Mair KJ; Hotter A; Poewe W; Seppi K
    Mov Disord; 2016 Sep; 31(9):1405-8. PubMed ID: 27273736
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Substantia nigra hyperechogenicity does not correlate with motor features in Parkinson's disease.
    Jesus-Ribeiro J; Sargento-Freitas J; Sousa M; Silva F; Freire A; Januário C
    J Neurol Sci; 2016 May; 364():9-11. PubMed ID: 27084206
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transcranial brain sonography findings in clinical subgroups of idiopathic Parkinson's disease.
    Walter U; Dressler D; Wolters A; Wittstock M; Benecke R
    Mov Disord; 2007 Jan; 22(1):48-54. PubMed ID: 17083096
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prodromal features for Parkinson's disease--baseline data from the TREND study.
    Gaenslen A; Wurster I; Brockmann K; Huber H; Godau J; Faust B; Lerche S; Eschweiler GW; Maetzler W; Berg D
    Eur J Neurol; 2014 May; 21(5):766-72. PubMed ID: 24612314
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sonographic abnormality of the substantia nigra in melanoma patients.
    Rumpf JJ; Weise D; Fricke C; Wetzig T; Simon JC; Classen J
    Mov Disord; 2013 Feb; 28(2):219-23. PubMed ID: 23114984
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Progression of prodromal motor and non-motor symptoms in the premotor phase study - 2-year follow-up data.
    Liepelt-Scarfone I; Brändle B; Yilmaz R; Gauss K; Schaeffer E; Timmers M; Wurster I; Brockmann K; Maetzler W; Van Nueten L; Streffer JR; Berg D
    Eur J Neurol; 2017 Nov; 24(11):1369-1374. PubMed ID: 28872736
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Substantia nigra hyperechogenicity and Parkinson's disease risk in patients with essential tremor.
    Sprenger FS; Wurster I; Seppi K; Stockner H; Scherfler C; Sojer M; Schmidauer C; Berg D; Poewe W
    Mov Disord; 2016 Apr; 31(4):579-83. PubMed ID: 26893155
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlation of dopaminergic terminal dysfunction and microstructural abnormalities of the basal ganglia and the olfactory tract in Parkinson's disease.
    Scherfler C; Esterhammer R; Nocker M; Mahlknecht P; Stockner H; Warwitz B; Spielberger S; Pinter B; Donnemiller E; Decristoforo C; Virgolini I; Schocke M; Poewe W; Seppi K
    Brain; 2013 Oct; 136(Pt 10):3028-37. PubMed ID: 24014521
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The specificity and sensitivity of transcranial ultrasound in the differential diagnosis of Parkinson's disease: a prospective blinded study.
    Gaenslen A; Unmuth B; Godau J; Liepelt I; Di Santo A; Schweitzer KJ; Gasser T; Machulla HJ; Reimold M; Marek K; Berg D
    Lancet Neurol; 2008 May; 7(5):417-24. PubMed ID: 18394965
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Place value of transcranial sonography in early diagnosis of Parkinson's disease.
    Berg D; Gaenslen A
    Neurodegener Dis; 2010; 7(5):291-9. PubMed ID: 20616564
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Accelerometer-based quantitative analysis of axial nocturnal movements differentiates patients with Parkinson's disease, but not high-risk individuals, from controls.
    Louter M; Maetzler W; Prinzen J; van Lummel RC; Hobert M; Arends JB; Bloem BR; Streffer J; Berg D; Overeem S; Liepelt-Scarfone I
    J Neurol Neurosurg Psychiatry; 2015 Jan; 86(1):32-7. PubMed ID: 24777169
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reproducibility and diagnostic accuracy of substantia nigra sonography for the diagnosis of Parkinson's disease.
    van de Loo S; Walter U; Behnke S; Hagenah J; Lorenz M; Sitzer M; Hilker R; Berg D
    J Neurol Neurosurg Psychiatry; 2010 Oct; 81(10):1087-92. PubMed ID: 20543186
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of patients with longstanding idiopathic REM sleep behavior disorder.
    Iranzo A; Stefani A; Serradell M; Martí MJ; Lomeña F; Mahlknecht P; Stockner H; Gaig C; Fernández-Arcos A; Poewe W; Tolosa E; Högl B; Santamaria J;
    Neurology; 2017 Jul; 89(3):242-248. PubMed ID: 28615430
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk factors and prodromal markers and the development of Parkinson's disease.
    Lerche S; Seppi K; Behnke S; Liepelt-Scarfone I; Godau J; Mahlknecht P; Gaenslen A; Brockmann K; Srulijes K; Huber H; Wurster I; Stockner H; Kiechl S; Willeit J; Gasperi A; Fassbender K; Poewe W; Berg D
    J Neurol; 2014 Jan; 261(1):180-7. PubMed ID: 24190794
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hyperechogenicity of the substantia nigra in Parkinson's disease.
    Ressner P; Skoloudík D; Hlustík P; Kanovský P
    J Neuroimaging; 2007 Apr; 17(2):164-7. PubMed ID: 17441838
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.